Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 5, 2019
Inspire Medical Systems, Inc. Announces Additional Positive Coverage Policies Issued by Five Blue Cross Blue Shield Healthcare Plans
MINNEAPOLIS, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative ...
February 5, 2019
EDAP TMS SA : UCI Health Medical Center Becomes First in the U.S. to Treat Patients Using EDAP's Breakthrough Focal One® HIFU Technology
LYON, France, February 5, 2019 -- EDAP TMS SA (EDAP) ("the Company"), the global leader in therapeutic ultrasound, today announced that UCI Health (UCI) has ...
February 5, 2019
Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference
FLORHAM PARK, N.J., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs ...
February 5, 2019
BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
TEL AVIV, Israel, Feb. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced ...
February 5, 2019
Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States
BOSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based ...
February 5, 2019
aTyr Pharma to Present at the BIO CEO & Investor Conference
SAN DIEGO, Feb. 05, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
February 5, 2019
AIT Therapeutics Schedules Fiscal Third Quarter 2019 Financial Results Conference Call and Webcast
NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide ...
February 5, 2019
Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2018 Financial Results on February 26
MINNEAPOLIS, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative ...
February 5, 2019
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
February 4, 2019
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
MONMOUTH JUNCTION, N.J., Feb. 4, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill ...
February 4, 2019
Oncolytics Biotech to Present at the 21st Annual BIO CEO & Investor Conference
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 4, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic ...
February 4, 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
TEL AVIV, Israel, Feb. 4, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and ...
February 4, 2019
Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
BUFFALO, N.Y., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for ...
February 4, 2019
Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering
ISFIYA, Israel, Feb. 4, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and ...
February 4, 2019
Allakos to Host Investor Day on February 19 in New York City
REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell ...
February 4, 2019
Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
PALO ALTO, Calif., Feb. 4, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced ...
February 4, 2019
AIT Receives $3.15 Million Milestone Payment from Commercialization Partner Circassia Pharmaceuticals
GARDEN CITY, N.Y. and REHOVOT, Israel, Feb. 04, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
February 4, 2019
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with ...
February 4, 2019
Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting
BRISBANE, Calif.--(BUSINESS WIRE)-- — Nine Abstracts Featured, Including Data on Longer-Term AR101 Efficacy and Safety and PALISADE Accidental Exposures — Aimmune Therapeutics, Inc. (AIMT), a ...
February 4, 2019
INVENTIVA : New results on lanifibranor to be presented at the International Liver Congress 2019
Daix (France), February 4, 2019 - Inventiva S.A. ("Inventiva"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis ("NASH"), systemic sclerosis and mucopolysaccharidosis ("MPS"), today ...
Page 16 of 138